Journal Watch · Bioengineering & Translational Medicine · 2026
Dynamic and living devices for overcoming fibrosis of implanted biomaterials.
Here, we highlight medical applications where active antifibrotic strategies outperform passive strategies in terms of device lifetimes and therapeutic outcomes, outline engineering design considerations for integrating active strategies, and discuss challenges in developing dynamic and living implants.
TL;DR
Here, we highlight medical applications where active antifibrotic strategies outperform passive strategies in terms of device lifetimes and therapeutic outcomes, outline engineering design considerations for integrating active strategies, and discuss challenges in developing dynamic and living implants.
Key findings
- Recent advancements in microfabrication and mechanotherapy have led engineers to incorporate smart and active mechanical actuation systems into implantable devices that use pressure, vibration, and integrated electronics to perpetually overcome effects of the foreign body response.
- Here, we highlight medical applications where active antifibrotic strategies outperform passive strategies in terms of device lifetimes and therapeutic outcomes, outline engineering design considerations for integrating active strategies, and discuss challenges in developing dynamic and living implants.
What they did
Most strategies to overcome fibrosis take a passive, materials-driven approach to mitigate the chemical and mechanical mismatch at the tissue-implant interface through superficial or structural implant modifications.
Full abstract (original)
Background: The fibrotic encapsulation of implantable medical devices reduces diffusion-based mass transport and electrical conductivity between the tissue and implant, limiting many devices to weeks-long rather than years-long lifetimes.
What they did: Most strategies to overcome fibrosis take a passive, materials-driven approach to mitigate the chemical and mechanical mismatch at the tissue-implant interface through superficial or structural implant modifications.
Results & conclusions: Recent advancements in microfabrication and mechanotherapy have led engineers to incorporate smart and active mechanical actuation systems into implantable devices that use pressure, vibration, and integrated electronics to perpetually overcome effects of the foreign body response. Here, we highlight medical applications where active antifibrotic strategies outperform passive strategies in terms of device lifetimes and therapeutic outcomes, outline engineering design considerations for integrating active strategies, and discuss challenges in developing dynamic and living implants.
Abstract © the authors / Bioengineering & Translational Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/btm2.70048 · PubMed 42016856.
Why it matters for pharma & biotech
- Relevant to Biotechnology & Methods teams tracking Bioengineering & Translational Medicine for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Bioengineering & Translational Medicine study find?
Here, we highlight medical applications where active antifibrotic strategies outperform passive strategies in terms of device lifetimes and therapeutic outcomes, outline engineering design considerations for integrating active strategies, and discuss challenges in developing dynamic and living implants.
What type of study is this?
It is a research study, published in Bioengineering & Translational Medicine in 2026. Most strategies to overcome fibrosis take a passive, materials-driven approach to mitigate the chemical and mechanical mismatch at the tissue-implant interface through superficial or structural implant modifications.
Where can I read the original paper?
The original is at the publisher via DOI 10.1002/btm2.70048. PubMed ID: 42016856. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/dynamic-and-living-devices-for-overcoming-fibrosis-of-implanted-biomater-270048/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides